PL2491028T3 - Związki indazolowe i pirazolopirydynowe jako antagoniści receptora CCR1 - Google Patents
Związki indazolowe i pirazolopirydynowe jako antagoniści receptora CCR1Info
- Publication number
- PL2491028T3 PL2491028T3 PL10768356T PL10768356T PL2491028T3 PL 2491028 T3 PL2491028 T3 PL 2491028T3 PL 10768356 T PL10768356 T PL 10768356T PL 10768356 T PL10768356 T PL 10768356T PL 2491028 T3 PL2491028 T3 PL 2491028T3
- Authority
- PL
- Poland
- Prior art keywords
- indazole
- receptor antagonists
- ccr1 receptor
- pyrazolopyridine compounds
- pyrazolopyridine
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/62—Oxygen or sulfur atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Diabetes (AREA)
- Biomedical Technology (AREA)
- Pulmonology (AREA)
- Dermatology (AREA)
- Rheumatology (AREA)
- Heart & Thoracic Surgery (AREA)
- Psychiatry (AREA)
- Transplantation (AREA)
- Pain & Pain Management (AREA)
- Communicable Diseases (AREA)
- Cardiology (AREA)
- Hospice & Palliative Care (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Urology & Nephrology (AREA)
- Endocrinology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Emergency Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US25359009P | 2009-10-21 | 2009-10-21 | |
EP10768356.7A EP2491028B1 (en) | 2009-10-21 | 2010-10-19 | Indazole and pyrazolopyridine compounds as ccr1 receptor antagonists |
PCT/US2010/053142 WO2011049917A1 (en) | 2009-10-21 | 2010-10-19 | Indazole and pyrazolopyridine compounds as ccr1 receptor antagonists |
Publications (1)
Publication Number | Publication Date |
---|---|
PL2491028T3 true PL2491028T3 (pl) | 2014-05-30 |
Family
ID=43126891
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PL10768356T PL2491028T3 (pl) | 2009-10-21 | 2010-10-19 | Związki indazolowe i pirazolopirydynowe jako antagoniści receptora CCR1 |
Country Status (29)
Country | Link |
---|---|
US (1) | US9056858B2 (pl) |
EP (1) | EP2491028B1 (pl) |
JP (1) | JP5542946B2 (pl) |
KR (1) | KR20120087923A (pl) |
CN (1) | CN102666526A (pl) |
AP (1) | AP2012006204A0 (pl) |
AU (1) | AU2010308277A1 (pl) |
BR (1) | BR112012009331A2 (pl) |
CA (1) | CA2778060A1 (pl) |
CL (1) | CL2012000967A1 (pl) |
CO (1) | CO6531488A2 (pl) |
DK (1) | DK2491028T3 (pl) |
EA (1) | EA021015B1 (pl) |
EC (1) | ECSP12011904A (pl) |
ES (1) | ES2444780T3 (pl) |
GE (1) | GEP20146103B (pl) |
HR (1) | HRP20140213T1 (pl) |
IL (1) | IL218823A0 (pl) |
IN (1) | IN2012DN03449A (pl) |
MA (1) | MA33675B1 (pl) |
MX (1) | MX2012004644A (pl) |
NZ (1) | NZ599132A (pl) |
PE (1) | PE20121433A1 (pl) |
PL (1) | PL2491028T3 (pl) |
PT (1) | PT2491028E (pl) |
RS (1) | RS53130B (pl) |
SI (1) | SI2491028T1 (pl) |
TN (1) | TN2012000180A1 (pl) |
WO (1) | WO2011049917A1 (pl) |
Families Citing this family (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2009134666A1 (en) | 2008-04-29 | 2009-11-05 | Boehringer Ingelheim International Gmbh | Indazole compounds as ccr1 receptor antagonists |
CA2722811C (en) | 2008-05-06 | 2016-07-05 | Boehringer Ingelheim International Gmbh | Pyrazole compounds as ccr1 antagonists |
AU2009296839A1 (en) | 2008-09-26 | 2010-04-01 | Boehringer Ingelheim International Gmbh | Azaindazole compounds as CCR1 receptor antagonists |
NZ599132A (en) | 2009-10-21 | 2014-05-30 | Boehringer Ingelheim Int | Indazole and pyrazolopyridine compounds as ccr1 receptor antagonists |
EP2493875B1 (en) * | 2009-10-27 | 2014-08-06 | Boehringer Ingelheim International GmbH | Heterocyclic compounds as ccr1 receptor antagonists |
EP2563787B1 (en) | 2010-04-30 | 2014-11-26 | Boehringer Ingelheim International GmbH | Azaindazole amide compounds as ccr1 receptor antagonists |
EP2655371B1 (en) | 2010-12-23 | 2015-02-25 | Boehringer Ingelheim International GmbH | Pyrazolopiperidine compounds as ccr1 receptor antagonists |
CA2852160A1 (en) | 2011-10-28 | 2013-05-02 | Galderma Research & Development | New leukocyte infiltrate markers for rosacea and uses thereof |
JP6282759B2 (ja) | 2014-04-14 | 2018-02-21 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | Rorガンマのモジュレーターとしての化合物 |
CN112707831A (zh) * | 2021-02-05 | 2021-04-27 | 阿里生物新材料(常州)有限公司 | 一种3-(1-氨基环丙基)苯甲酸甲酯的合成方法 |
Family Cites Families (60)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5242931A (en) | 1988-06-09 | 1993-09-07 | Kyowa Hakko Kogyo Co., Ltd. | Tricyclic compounds as TXA2 antagonists |
US4999363A (en) | 1988-06-09 | 1991-03-12 | Kyowa Hakko Kogyo Co., Ltd. | Tricyclic compounds |
US5750542A (en) | 1993-09-28 | 1998-05-12 | Pfizer | Benzisoxazole and benzisothizole derivatives as cholinesterase inhibitors |
CZ289756B6 (cs) | 1991-03-28 | 2002-04-17 | Eisai Co., Ltd. | Heterocyklicko-cyklické aminové deriváty, meziprodukty postupu přípravy těchto sloučenin, farmaceutický prostředek a pouľití uvedených derivátů |
US5612360A (en) | 1992-06-03 | 1997-03-18 | Eli Lilly And Company | Angiotensin II antagonists |
RU2105005C1 (ru) | 1992-07-03 | 1998-02-20 | Кумиай Кемикал Индастри Ко., Лтд. | Конденсированное гетероциклическое производное, способ его получения и гербицидное средство |
EP0657450B1 (en) | 1993-06-25 | 1998-09-09 | KumaiI Chemical Industry Co., Ltd. | Indazolesulfonylurea derivative, use thereof, and intermediate for production thereof |
CA2207201A1 (en) | 1994-12-06 | 1996-06-13 | Caroline Henry | Azetidine, pyrrolidine and piperidine derivatives as 5ht1 receptor agonists |
GB9519563D0 (en) | 1995-09-26 | 1995-11-29 | Merck Sharp & Dohme | Therapeutic agents |
GB9523583D0 (en) | 1995-11-17 | 1996-01-17 | Merck Sharp & Dohme | Therapeutic agents |
US5760028A (en) | 1995-12-22 | 1998-06-02 | The Dupont Merck Pharmaceutical Company | Integrin receptor antagonists |
JP2000501105A (ja) | 1995-12-22 | 2000-02-02 | デュポン ファーマシューティカルズ カンパニー | 新規なインテグリン受容体アンタゴニスト |
JPH101478A (ja) | 1996-06-11 | 1998-01-06 | Kumiai Chem Ind Co Ltd | インダゾールスルホニル尿素誘導体及び除草剤 |
GB9615449D0 (en) | 1996-07-23 | 1996-09-04 | Merck Sharp & Dohme | Therapeutic agents |
CA2309175A1 (en) | 1997-11-04 | 1999-05-14 | Pfizer Products Inc. | Therapeutically active compounds based on indazole bioisostere replacement of catechol in pde4 inhibitors |
US6331640B1 (en) | 1998-10-13 | 2001-12-18 | Hoffmann-La Roche Inc. | Diaminopropionic acid derivatives |
DE60022508T2 (de) | 1999-06-14 | 2006-06-08 | Eli Lilly And Co., Indianapolis | Inhibitoren von serin proteasen |
WO2000076970A2 (en) | 1999-06-14 | 2000-12-21 | Eli Lilly And Company | Serine protease inhibitors |
WO2001000656A2 (en) | 1999-06-29 | 2001-01-04 | Ortho-Mcneil Pharmaceutical, Inc. | Novel indazole peptidomimetics as thrombin receptor antagonists |
KR20020095186A (ko) | 2000-03-02 | 2002-12-20 | 엔디씨 인프라레드 엔지니어링 리미티드 | 전자기 검출 장치 |
GB0030304D0 (en) | 2000-12-13 | 2001-01-24 | Lilly Co Eli | Compounds |
GB0030306D0 (en) | 2000-12-13 | 2001-01-24 | Lilly Co Eli | Compounds |
GB0030305D0 (en) | 2000-12-13 | 2001-01-24 | Lilly Co Eli | Compounds |
GB0030303D0 (en) | 2000-12-13 | 2001-01-24 | Lilly Co Eli | Compounds |
US20050009876A1 (en) | 2000-07-31 | 2005-01-13 | Bhagwat Shripad S. | Indazole compounds, compositions thereof and methods of treatment therewith |
US7211594B2 (en) | 2000-07-31 | 2007-05-01 | Signal Pharmaceuticals, Llc | Indazole compounds and compositions thereof as JNK inhibitors and for the treatment of diseases associated therewith |
US6897231B2 (en) | 2000-07-31 | 2005-05-24 | Signal Pharmaceuticals, Inc. | Indazole derivatives as JNK inhibitors and compositions and methods related thereto |
US7058826B2 (en) | 2000-09-27 | 2006-06-06 | Amphus, Inc. | System, architecture, and method for logical server and other network devices in a dynamically configurable multi-server network environment |
US20020052373A1 (en) | 2000-10-26 | 2002-05-02 | Zorn Stevin H. | Combination treatment for dementia or cognitive deficits associated with alzheimer's disease and parkinson's disease |
AU2002363250A1 (en) | 2001-11-01 | 2003-05-12 | Icagen, Inc. | Pyrazole-amides and-sulfonamides |
ES2343787T3 (es) | 2002-04-11 | 2010-08-10 | Boehringer Ingelheim Pharmaceuticals Inc. | Derivados de amidas heterociclicas de utilizacion como inhibidores de citoquina. |
IL164209A0 (en) | 2002-05-31 | 2005-12-18 | Eisai Co Ltd | Pyrazole derivatives and pharmaceutical compositions containing the same |
DE60328690D1 (de) | 2002-06-12 | 2009-09-17 | Chemocentryx Inc | 1-aryl-4-substituierte piperazin-derivate zur verwendung als ccr1-antagonisten zur behandlung von entzündungen und immunerkrankungen |
CA2494942A1 (en) | 2002-08-08 | 2004-02-19 | Boehringer Ingelheim Pharmaceuticals, Inc. | Substituted benzimidazole compounds |
TW200500341A (en) | 2002-11-12 | 2005-01-01 | Astrazeneca Ab | Novel compounds |
SE0203825D0 (sv) | 2002-12-20 | 2002-12-20 | Astrazeneca Ab | Novel fused heterocycles and uses thereof |
US7129264B2 (en) | 2003-04-16 | 2006-10-31 | Bristol-Myers Squibb Company | Biarylmethyl indolines and indoles as antithromboembolic agents |
US20040220170A1 (en) | 2003-05-01 | 2004-11-04 | Atkinson Robert N. | Pyrazole-amides and sulfonamides as sodium channel modulators |
EP1664052B1 (en) | 2003-08-15 | 2009-02-18 | AstraZeneca AB | Fused heterocycles as inhibitors of glutamate racemase (muri) |
AU2006216917A1 (en) | 2005-02-24 | 2006-08-31 | Merck Sharp & Dohme Corp. | Benzazole potentiators of metabotropic glutamate receptors |
GB0504828D0 (en) | 2005-03-09 | 2005-04-13 | Merck Sharp & Dohme | Therapeutic agents |
CA2609053C (en) | 2005-05-17 | 2017-04-25 | Sarcode Corporation | Compositions and methods for treatment of eye disorders |
US20070155738A1 (en) | 2005-05-20 | 2007-07-05 | Alantos Pharmaceuticals, Inc. | Heterobicyclic metalloprotease inhibitors |
NZ564258A (en) | 2005-06-22 | 2011-02-25 | Chemocentryx Inc | Azaindazole compounds and methods of use |
DK1924561T3 (da) | 2005-09-01 | 2012-12-10 | Lilly Co Eli | 6-arylalkylamino-2,3,4,5-tetrahydro-1h-benzo[d]azepiner as 5-ht2c-receptor agonister |
JP2009513677A (ja) * | 2005-10-25 | 2009-04-02 | スミスクライン・ビーチャム・コーポレイション | 化合物 |
EP2044055A4 (en) | 2006-07-21 | 2011-03-23 | Takeda Pharmaceutical | amide compounds |
BRPI0806898A2 (pt) | 2007-01-19 | 2015-07-14 | Ardea Biosciences Inc | Inibidores de mek |
AU2008269513B2 (en) | 2007-06-26 | 2011-06-16 | Astrazeneca Ab | 1-cyanocyclopropyl-derivatives as cathepsin K inhibitors |
CA2696725A1 (en) | 2007-08-10 | 2009-03-26 | Crystalgenomics, Inc. | Pyridine derivatives and methods of use thereof |
GB0716292D0 (en) | 2007-08-21 | 2007-09-26 | Biofocus Dpi Ltd | Imidazopyrazine compounds |
PL2225238T3 (pl) | 2007-11-29 | 2015-03-31 | Boehringer Ingelheim Int | Pochodne amidów kwasu 6,7-dihydro-5H-imidazo[1,2-a]imidazolo-3-karboksylowego |
WO2009134666A1 (en) | 2008-04-29 | 2009-11-05 | Boehringer Ingelheim International Gmbh | Indazole compounds as ccr1 receptor antagonists |
CA2722811C (en) | 2008-05-06 | 2016-07-05 | Boehringer Ingelheim International Gmbh | Pyrazole compounds as ccr1 antagonists |
AU2009296839A1 (en) | 2008-09-26 | 2010-04-01 | Boehringer Ingelheim International Gmbh | Azaindazole compounds as CCR1 receptor antagonists |
NZ599132A (en) | 2009-10-21 | 2014-05-30 | Boehringer Ingelheim Int | Indazole and pyrazolopyridine compounds as ccr1 receptor antagonists |
EP2493875B1 (en) | 2009-10-27 | 2014-08-06 | Boehringer Ingelheim International GmbH | Heterocyclic compounds as ccr1 receptor antagonists |
CN102596908A (zh) | 2009-12-08 | 2012-07-18 | 贝林格尔.英格海姆国际有限公司 | 用于制备取代的吲唑和氮杂吲唑化合物的中间体的合成方法 |
EP2563787B1 (en) | 2010-04-30 | 2014-11-26 | Boehringer Ingelheim International GmbH | Azaindazole amide compounds as ccr1 receptor antagonists |
EP2655371B1 (en) | 2010-12-23 | 2015-02-25 | Boehringer Ingelheim International GmbH | Pyrazolopiperidine compounds as ccr1 receptor antagonists |
-
2010
- 2010-10-19 NZ NZ599132A patent/NZ599132A/en not_active IP Right Cessation
- 2010-10-19 PE PE2012000493A patent/PE20121433A1/es not_active Application Discontinuation
- 2010-10-19 KR KR1020127010143A patent/KR20120087923A/ko not_active Application Discontinuation
- 2010-10-19 PT PT107683567T patent/PT2491028E/pt unknown
- 2010-10-19 BR BR112012009331A patent/BR112012009331A2/pt not_active IP Right Cessation
- 2010-10-19 US US13/499,939 patent/US9056858B2/en active Active
- 2010-10-19 JP JP2012535292A patent/JP5542946B2/ja active Active
- 2010-10-19 MX MX2012004644A patent/MX2012004644A/es active IP Right Grant
- 2010-10-19 EA EA201200602A patent/EA021015B1/ru not_active IP Right Cessation
- 2010-10-19 SI SI201030538T patent/SI2491028T1/sl unknown
- 2010-10-19 AU AU2010308277A patent/AU2010308277A1/en not_active Abandoned
- 2010-10-19 WO PCT/US2010/053142 patent/WO2011049917A1/en active Application Filing
- 2010-10-19 IN IN3449DEN2012 patent/IN2012DN03449A/en unknown
- 2010-10-19 PL PL10768356T patent/PL2491028T3/pl unknown
- 2010-10-19 RS RS20140024A patent/RS53130B/en unknown
- 2010-10-19 DK DK10768356.7T patent/DK2491028T3/da active
- 2010-10-19 CN CN2010800578454A patent/CN102666526A/zh active Pending
- 2010-10-19 CA CA2778060A patent/CA2778060A1/en not_active Abandoned
- 2010-10-19 GE GEAP201012715A patent/GEP20146103B/en unknown
- 2010-10-19 ES ES10768356.7T patent/ES2444780T3/es active Active
- 2010-10-19 EP EP10768356.7A patent/EP2491028B1/en active Active
- 2010-10-19 AP AP2012006204A patent/AP2012006204A0/xx unknown
-
2012
- 2012-03-25 IL IL218823A patent/IL218823A0/en unknown
- 2012-04-16 CL CL2012000967A patent/CL2012000967A1/es unknown
- 2012-04-16 MA MA34779A patent/MA33675B1/fr unknown
- 2012-04-19 TN TNP2012000180A patent/TN2012000180A1/en unknown
- 2012-04-26 CO CO12068976A patent/CO6531488A2/es active IP Right Grant
- 2012-05-16 EC ECSP12011904 patent/ECSP12011904A/es unknown
-
2014
- 2014-03-10 HR HRP20140213AT patent/HRP20140213T1/hr unknown
Also Published As
Publication number | Publication date |
---|---|
SI2491028T1 (sl) | 2014-03-31 |
CO6531488A2 (es) | 2012-09-28 |
TN2012000180A1 (en) | 2013-12-12 |
PE20121433A1 (es) | 2012-11-10 |
CL2012000967A1 (es) | 2012-09-14 |
US20120270870A1 (en) | 2012-10-25 |
MX2012004644A (es) | 2012-05-08 |
JP2013508376A (ja) | 2013-03-07 |
EP2491028B1 (en) | 2013-12-11 |
AP2012006204A0 (en) | 2012-04-30 |
JP5542946B2 (ja) | 2014-07-09 |
BR112012009331A2 (pt) | 2019-09-24 |
NZ599132A (en) | 2014-05-30 |
US9056858B2 (en) | 2015-06-16 |
ES2444780T3 (es) | 2014-02-26 |
EA201200602A1 (ru) | 2012-12-28 |
EP2491028A1 (en) | 2012-08-29 |
IL218823A0 (en) | 2012-06-28 |
CN102666526A (zh) | 2012-09-12 |
EA021015B1 (ru) | 2015-03-31 |
PT2491028E (pt) | 2014-02-04 |
HRP20140213T1 (hr) | 2014-04-11 |
WO2011049917A1 (en) | 2011-04-28 |
GEP20146103B (en) | 2014-05-27 |
AU2010308277A1 (en) | 2012-04-26 |
KR20120087923A (ko) | 2012-08-07 |
CA2778060A1 (en) | 2011-04-28 |
MA33675B1 (fr) | 2012-10-01 |
RS53130B (en) | 2014-06-30 |
ECSP12011904A (es) | 2012-10-30 |
IN2012DN03449A (pl) | 2015-10-23 |
DK2491028T3 (da) | 2014-01-13 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
IL210857A0 (en) | Azaindazole compounds as ccr1 receptor antagonists | |
IL218823A0 (en) | Indazole and pyrazolopyridine compounds as ccr1 receptor antagonists | |
HK1188211A1 (zh) | 受體拮抗劑 | |
AP3170A (en) | New CCR2 receptor antagonists and uses thereof | |
EP2344497A4 (en) | AZAINDOLE DERIVATIVES AS CRTH2 RECEPTOR ANTAGONISTS | |
ZA201202029B (en) | Androgen receptor antagonists and uses thereof | |
IL212551A0 (en) | Cxcr4 receptor compounds | |
HK1159621A1 (en) | Pyrazole derivatives used as ccr4 receptor antagonists | |
EP2427430A4 (en) | 5-OXO-ETE RECEPTOR ANTAGONIST COMPOUNDS | |
EP2480077A4 (en) | Novel pyrrolidines as glucagonone receptor agonists, compositions thereof, and methods of use | |
HK1163063A1 (en) | Novel pyrazole-3-carboxamide derivate having 5-ht2b receptor antagonist activity 5-ht2b -3- | |
HK1179619A1 (en) | (3 -methylpyrrolidin- 3 - yl) methyl pyridinyl ether derivatives and their use as nk-3 receptor antagonists (3---3-)- nk-3 | |
EP2566494A4 (en) | CXCR4 RECEPTOR COMPOUNDS | |
IL241743A0 (en) | Non-competitive nicotinic receptor antagonists | |
IL217965A0 (en) | Bicyclic heterocycles and their use as ccr2 receptor antagonists | |
EP2539706A4 (en) | ARYLPIPERAZONE ANTAGONISTS OF OPIOID RECEPTORS | |
HK1186176A1 (en) | Glycine derivatives and their use as muscarinic receptor antagonists | |
GB0900756D0 (en) | EP4 Receptor antagonists | |
GB0900755D0 (en) | Ep4 receptor antagonists | |
GB0900754D0 (en) | EP4 Receptor antagonists | |
GB0901836D0 (en) | EP4 receptor antagonists | |
ZA200906849B (en) | Mineralcorticoid receptor antagonists for the treatment of endomertriosis | |
GB0922455D0 (en) | Ep2 receptor antagonists |